-
Summit Therapeutics Stock Slumps After Partner Akeso Gets FDA Nod For Cancer Drug: Retail’s Optimistic
26 Apr 2025 00:39 GMT
… late-stage clinical trials.
Summit Therapeutics stock … Food and Drug Administration (FDA) approved its partner pharmaceutical company Akeso … carboplatin and gemcitabine for the treatment of certain … multiple late-stage clinical trials.
Earlier this month …
-
Akeso hot with FDA cancer win, nods in China, new data
25 Apr 2025 20:57 GMT
… disclosed April 23 by Akeso Pharmaceuticals Inc. related to Harmoni-6 … light from the U.S. FDA April 24 for marketing the … or carboplatin and gemcitabine for the first-line treatment of adult recurrent … Asia-Pacific China U.S. FDA
-
FDA approves Akeso’s monoclonal antibody for nasopharyngeal carcinoma
25 Apr 2025 14:55 GMT
The US Food and Drug Administration (FDA) has granted approval to … or carboplatin and gemcitabine as a first-line treatment.
Akeso’s … for the antibody.
These trials have shown the clinical benefits … and Chia Tai-Tianqing Pharmaceutical Group’s joint venture …
-
Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma
25 Apr 2025 11:43 GMT
… access to these treatments through national medical insurance. Now, … or completed pivotal clinical trials evaluating the safety and … cisplatin and gemcitabine as the first-line treatment for … responsibilities of a Chinese pharmaceutical company through its …
-
FDA Oks Penpulimab for First-Line Non-Keratinizing Nasopharyngeal Carcinoma
25 Apr 2025 01:21 GMT
… Study AK105-202 (NCT03866967).
The FDA has granted approval to the … or carboplatin and gemcitabine for the first-line treatment of adult patients … a randomized, double-blind, multicenter trial in patients with recurrent or …
-
Akeso Announces FDA Approval for Penpulimab-kcqx in Two BLA Indications for Comprehensive Treatment of Advanced Nasopharyngeal Carcinoma
25 Apr 2025 01:57 GMT
… and gemcitabine for the first-line treatment of … standards in pharmaceutical quality management.
The FDA's … -class innovative biological medicines. Founded in 2012, … candidates have entered clinical trials (including 15 bispecific…
-
FDA Approves Penpulimab-Kcqx for Indications in Nonkeratinizing Nasopharyngeal Carcinoma
24 Apr 2025 23:32 GMT
… gemcitabine (Gemzar; Eli Lilly and Company) for the first-line treatment … -202 (NCT03866967) clinical trials.1-3
The efficacy of … multicenter phase 3 clinical trial AK105-304 (NCT04974398), which … months, according to the FDA. Additionally, the recommended …
-
Lactylation Score May Predict Bladder Cancer Treatment Outcome
24 Apr 2025 22:00 GMT
… efficacy of immune checkpoint inhibitor treatment, according to researchers.
… MD, PhD, of Biruni University Medical School, Istanbul, Turkey, and … six commonly used chemotherapeutic agents (gemcitabine, cisplatin, vinblastine, doxorubicin, docetaxel …
-
FDA Approves Penpulimab-kcqx For Nasopharyngeal Carcinoma
24 Apr 2025 21:13 GMT
… Drug Administration (FDA) has approved penpulimab-kcqx with cisplatin or carboplatin and gemcitabine … responded partially or completely to treatment.
Pneumonitis: lung inflammation.
… gemcitabine was evaluated in Study AK105-304, a multicenter trial …
-
FDA Approves Penpulimab in Non-Keratinizing Nasopharyngeal Carcinoma
24 Apr 2025 20:40 GMT
… FDA has approved penpulimab-kcqx (Anike) with cisplatin or carboplatin and gemcitabine … as a first-line treatment for adult … the FDA decision came from the phase 3 AK105-304 trial … arm phase 2 AK105-202 trial (NCT03866967) in 125 …
About
© 1995-2025